| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8629568 | Diabetes Research and Clinical Practice | 2018 | 14 Pages |
Abstract
Based on current evidence, third-generation sulfonylureas such as gliclazide MR possess many of the properties desired of a type 2 diabetes drug including high glucose-lowering efficacy, once-daily oral administration, few side effects other than mild hypoglycemia, and cardiovascular safety.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Stephen Colagiuri, David Matthews, Lawrence A. Leiter, Siew Pheng Chan, Giorgio Sesti, Michel Marre,